Title : CAREVID for COVID-19: 14 Kenyan Herbs, No Clinical Progression
Abstract:
From 2005-2018, Dr. Mitch and Dr. Maria Medina treated hundreds of HIV/AIDS patients in Kenya with a 14-herb composition (CAREVID) that was approved as a complementary medicine by the Kenya Pharmacy and Poisons Board. The composition was granted 6 U.S. patents, U.S. Patent Nos. 7,556,830; 7,674,483; 8,053,002; 8,067,401; 8,404,284; and 8,697,660. In clinical use, CAREVID, resulted in at least 12 cases of sero-reversion (HIV-positive to HIV-negative). These seemingly-impossible events occurred among patients who were not using ARV’s. Among patients who were on HAART, most achieved undetectable viral loads rapidly. A few patients were transitioned from HAART to the herbal medicine after achieving undetectable viral loads. In at least one case, the herbal medicine was subsequently withdrawn, successfully, leading to a complete functional cure. In 2019, Dr. Mitch and Dr. Maria returned to the Philippines, Dr. Maria’s native country. With the emergence of the COVID-19 pandemic, they wondered if the herbal mixture might be effective against the new SARS-2-CoV virus. This led to a pilot study, conducted by Dr. Maria in the Philippines. In that study, 32 COVID-19 cases occurring in 31 patients at all stages of the illness were treated with CAREVID capsules, which are formulated from hydroethanolic extracts of the herbs. NONE of the treated patients experienced clinical progression. A new patent application, PCT-PH2021-050044, was filed on the new use. The new patent application can be extended to virtually any jurisdiction (155 countries) during the coming year. Dr. Mitch and Dr. Maria are actively looking for research and commercial partners in the further development of CAREVID, and are willing to discuss exclusive or non-exclusive licenses to the patent in your jurisdiction.
